manilatimes23d
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium
Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product ...
manilatimes12d
Spur Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for FLT201, Its Gene Therapy Candidate for Gaucher Disease
LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced positive feedback from its end-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting its ...